![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
JAB-21822 (glecirasib) is a KRAS G12C inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of KRAS G12C mutated pancreatic cancer.
Lead Product(s): Glecirasib
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
JAB-3312 is a highly selective SHP2 allosteric inhibitor, in combination with JAB-21822 (glecirasib), a KRAS G12C inhibitor is being evaluated for first-line non-small cell lung cancer patients with KRAS G12C mutations.
Lead Product(s): JAB-3312,Glecirasib
Therapeutic Area: Oncology Product Name: JAB-3312
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2024
Details:
JAB-21822 (glecirasib) is a KRAS G12C inhibitor developed by Jacobio and being developed in KRAS G12C-mutated locally advanced or metastatic pancreatic cancer patients.
Lead Product(s): Glecirasib,JAB-3312
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Glecirasib is a novel KRAS G12C inhibitor. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial int NSCLC in China.
Lead Product(s): Glecirasib,JAB-3312
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2023